Scottish drug discovery accelerator Cumulus Oncology has appointed Clare Doris as chief operating officer.
She is a University of Edinburgh neuroscience graduate, who trained at the Massachusetts Institute of Technology before becoming a life sciences entrepreneur with a record in building companies in the sector.
Doris held positions in clinical research organisation Aptuit and Quintiles before joining University of Edinburgh spin-out Aquila BioMedical as chief operating officer in 2011, where she led the company from its start-up phase through to acquisition by Concept Life Sciences (CLS) in 2017.
Doris was responsible for the company integration and broader CLS Biology services strategy in her vice-president role.
Clare Wareing, chief executive and co-founder of Cumulus Oncology, said: “Clare was instrumental in transforming the company from a start-up to a successful specialist service provider, while leading collaborations supporting value creation and fundraising efforts for a range of biotech companies.”
Doris added: “The fresh approach taken by Cumulus as it creates biotech companies around novel oncology assets builds value for all stakeholders and accelerates new therapies for patients.”
In February, Wareing said she was looking at growth opportunities in Europe and Asia, as well as adding two more newco subsidiaries and more senior team appointments.
Don't miss the latest headlines with our twice-daily newsletter - sign up here for free.
